ProCE Banner Activity

Importance of Early Recognition and Treatment of Eosinophilic Esophagitis

Clinical Thought

The prevalence of eosinophilic esophagitis has increased dramatically over the past 3 decades and contributes to substantial morbidity for patients. In this commentary, an expert reviews the importance of early diagnosis and treatment to prevent disease progression.

Released: September 07, 2022

Expiration: September 06, 2023

No longer available for credit.



Ikuo Hirano

Ikuo Hirano, MD

Professor of Medicine
Division of Gastroenterology and Hepatology
Northwestern University Feinberg School of Medicine
Chicago, Illinois


This activity is supported by an educational grant from Regeneron Pharmaceuticals, Inc. and Sanofi.

Provided by

ProCE Banner


Regeneron Pharmaceuticals, Inc.


Target Audience

Gastroenterology, allergy, and primary care NPs and PAs who care for patients with eosinophilic esophagitis


Ikuo Hirano, MD: consultant/advisor/speaker: Allakos, Arena, AstraZeneca, Ellodi/Adare, EsoCap Biotech, Gossamer Bio, Lilly, Meritage Pharma, Phathom, Receptos/Celgene, Sanofi/Regeneron, Shire a Takeda company; researcher: Allakos, Ellodi/Adare, Meritage Pharma, Receptos/Celgene, Regeneron, Shire a Takeda company.

None of the members of the Planning Committee or PCE staff have any relevant financial relationships to disclose.



Additional Information

Program Medium

This program has been made available online.